Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins

• Published in: Cancer research (Chicago, Ill.) Ill.), 1982-03, Vol.42 (3), p.913-918
• Main Authors: Mazumder, A, Grimm, E A, Zhang, H Z, Rosenberg, S A
• Format: Article
• Language: English
• Subjects: Breast Neoplasms; Cells, Cultured; Cytotoxicity, Immunologic; Female; Growth Substances - pharmacology; Humans; Lectins - pharmacology; Lymphocyte Activation; Lymphocytes - drug effects; Lymphocytes - radiation effects; Melanoma; Neoplasm Metastasis; Neoplasms - pathology; Neoplasms - radiotherapy; Ovarian Neoplasms; Sarcoma
• ISSN: 0008-5472

Human peripheral blood lymphocytes (PBL), obtained from patients with a variety of cancers, were incubated in vitro with phytohemagglutinin, concanavalin A, and crude or lectin-free T-cell growth factors. The lectin-activated PBL of nine patients were capable of lysing fresh autologous tumor during a 4-hr 51Cr release assay. Multiple metastases from the same patient were equivalently lysed by these activated autologous PBL. No lysis of fresh PBL or lectin-induced lymphoblast cell targets was seen, although tumor, PBL, and lymphoblast cells were shown to be equally lysable using allosensitized cells. The activated cells could be expanded without loss of cytotoxicity in crude or lectin-free T-cell growth factors. The generation of cells lytic to fresh autologous tumor was dependent on the presence of adherent cells, although the lytic cell itself was not adherent. Proliferation was not involved in the induction of lytic cells since equal lysis was induced in irradiated and nonirradiated lymphocytes. Lectin was not required in the lytic assay, and the addition of alpha-methyl-D-mannoside to concanavalin A-activated lymphoid cells did not increase the lysis of fresh tumor cells. Activation by lectin for 3 days appears to be an efficient and convenient method for generating human cells lytic to fresh autologous tumor. These lytic cells may be of value for studies of the cell-mediated lysis of human tumor and possibly for tumor immunotherapy as well.